FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 6). | 於 2024年7月8日回購股份但尚未註銷 | | 27,200 | 0.0123 % | HKD | 32.65 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2024年7月8日 | | | | | | 7). | 於 2024年7月9日回購股份但尚未註銷 | | 64,800 | 0.0292 % | HKD | 32.9 | | | 變動日期 | 2024年7月9日 | | | | | | 8). | 於 2024年7月10日回購股份 ...

| 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2024年7月18日 | 192,191,381 | | 1,860,474 | | 194,051,855 | | 1). 購回股份 (股份被持作庫存股份) | | -16,000 | 0.0072 % | 16,000 RMB | 61.47 | | | 變動日期 2024年7月19日 | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) ...

Product Innovation - The fourth-generation hyaluronic acid product "Hai Mei Yue Bai" features human essential amino acids as cross-linking agents, significantly enhancing biocompatibility and long-term safety compared to traditional chemical cross-linkers [2] - The modification site of "Yue Bai" is the carboxyl group, which delays enzyme recognition, resulting in a longer maintenance time [2] - The introduction of amino acid cross-linking agents improves the traditional product's negative charge, promoting cell adhesion and proliferation, thus enhancing collagen generation [2] Market Strategy - The product's market preparation is progressing smoothly, with a nationwide pricing strategy aimed at the mid-to-high-end market [2] - The company emphasizes incremental sales growth without cannibalizing existing products like "Hai Mei" [2] - The company is actively participating in OEM sales, enhancing its market presence and product diversity [3] Business Development - The company is experiencing rapid growth in its third-generation hyaluronic acid product "Hai Mei," with a focus on maintaining market share and brand influence [2] - The integration of energy devices and biological materials is part of a comprehensive skin rejuvenation solution [3] - The company is expanding its product matrix beyond hyaluronic acid to include energy devices and other innovative materials [3] Research and Development - The company's R&D strategy includes three approaches: "Me too," "Me better," and "Me only," focusing on comprehensive skin rejuvenation [3] - Current R&D projects include enhanced water light injectables and medical-grade chitosan gels, aiming for product diversification [3] - The company is actively developing a range of products, including pain-free cross-linked sodium hyaluronate gels [3] Competitive Landscape - The company is strategically positioning itself in the competitive hyaluronic acid market by continuously launching innovative products [3] - The focus on product differentiation and effective marketing strategies has led to significant growth in the medical aesthetics sector [3]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 第 2 頁 共 8 頁 v 1.3.0 FF305 | 6). | 於 2024年7月8日回購股份但尚未註銷 | | 27,200 | 0.0123 % | HKD | 32.65 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2024年7月8日 | | | | | | 7). | 於 2024年7月9日回購股份但尚未註銷 | | 64,800 | 0.0292 % | HKD | 32.9 | | | 變動日期 | 2024年7月9日 | | | | | | 8). | 於 2024年7月10日回購股份但尚未註銷 | | 53,400 | 0.0241 % | HKD | 32.76 | | | 變動日期 | 2024年7月10日 | | | | | | 9). | 於 2024年7月11日回購股份但尚未註銷 | | ...

Summary of Conference Call on Haohai Biological Technology Company Overview - The conference call discusses Haohai Biological Technology, focusing on its innovative fourth-generation hyaluronic acid product, "Yuebai" [1][5]. Key Points and Arguments Product Innovation - The new product, Yuebai, is positioned as a revolutionary advancement in hyaluronic acid fillers, marking the transition to the 2.0 era of hyaluronic acid [1]. - Yuebai utilizes lysine as a cross-linking agent, enhancing biocompatibility and long-term safety compared to traditional chemical cross-linkers [1][2]. - The introduction of amino acid cross-linkers improves the product's structure, promoting cell adhesion and proliferation, thus enhancing its regenerative properties [2][4]. - The product has received international PCT patent approval, making it the first fully autonomous innovation from China in this field [5]. Market Strategy - The company has been preparing for the product's market launch for three years, generating anticipation among medical professionals [16]. - Sales training, product packaging, and pricing strategies are actively being developed, with a planned market launch in October [17][21]. - The pricing strategy aims for a mid-to-high range to ensure profitability while remaining accessible to consumers [19][20]. Sales and Growth Expectations - The company anticipates significant sales growth, projecting over 300 million yuan in sales for the year, largely driven by overseas markets [25]. - The introduction of Yuebai is expected to complement existing products without cannibalizing their sales, aiming for simultaneous growth [26][27]. Industry Context - The medical aesthetics industry is facing challenges due to consumer spending declines and price wars among institutions [39][41]. - Haohai aims to differentiate itself through continuous innovation and a diverse product line, including energy devices and skin rejuvenation solutions [30][32]. R&D and Future Plans - The company is committed to ongoing R&D, focusing on a wide range of products from skin treatments to energy devices [55][58]. - Future product lines will include various hyaluronic acid formulations and botulinum toxin products, with plans for clinical trials and market launches in the coming years [61][62]. Collaboration and Partnerships - Strategic partnerships with major medical aesthetic institutions, such as Meilai Group, are in place to promote the new product line [9][20]. - The company is also exploring international markets, with plans to introduce its products to Europe and the U.S. [50]. Additional Important Information - The company emphasizes the importance of safety and efficacy in its products, aiming to lead the market with innovative solutions [62][67]. - Haohai is focused on building a comprehensive marketing strategy that integrates online and offline channels to enhance brand visibility and consumer engagement [49][50]. This summary encapsulates the key discussions and strategic insights shared during the conference call, highlighting Haohai Biological Technology's innovative approach and market positioning in the medical aesthetics industry.

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | | 庫存股份變動 | | | | | 事件 | ...

FF305 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | 事件 | ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 ...

上海昊海生物科技股份有限公司 证券代码：688366 证券简称：昊海生科 公告编号：2024-035 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）全资子公司上海其胜 生物制剂有限公司于近日收到国家药品监督管理局颁发的关于注射用氨基酸交 联透明质酸钠凝胶产品（以下简称 "本产品"）的《中华人民共和国医疗器械 注册证》。现将相关情况公告如下： 一、医疗器械注册证的基本信息 产品名称：注射用氨基酸交联透明质酸钠凝胶 注册人名称：上海其胜生物制剂有限公司 型号、规格：0.5mL、0.6mL、0.75 mL、0.9 mL、1.0mL、1.1mL、1.25mL、 1.5mL、1.75mL、2.0mL 适用范围：适用于真皮组织中层至深层及皮下组织注射，纠正中度至重度鼻 唇沟皱纹。 注册证有效期：2024 年 7 月 10 日至 2029 年 7 月 9 日 二、产品的基本情况 关于自愿披露全资子公司注射用氨基酸交联透明质 酸钠凝胶产品获得医疗器械注册证的公告 本产品基于公司自主研发的全 ...